Nanosonics has entered financial year 2027 with continued growth from its trophon disinfection business, while advancing the commercial rollout of its CORIS endoscope reprocessing platform and commencing a new on-market share buyback of up to $40 million.
Revenue rose 3 per cent to $203.9 million in 2026, or 6 per cent to $211.5 million on a constant currency basis, with the reported result affected by the stronger Australian dollar.
Growth was driven by trophon placements, upgrades and recurring consumables and service revenue. Total device placements increased 9 per cent to 4,230 units, including a record 1,980 North American upgrades. The global installed base expanded 6 per cent to 39,230 systems.
Recurring revenue reached $149.2 million, up 2 per cent on a reported basis and 6 per cent at constant currency. Capital revenue rose 4 per cent to $54.7 million, supported by increased trophon3 sales and accelerating uptake of trophon2 Plus software upgrades.
Reported earnings fell 10 per cent to $16 million, although they rose 21 per cent to $21.6 million at constant currency. The company said the trophon business alone generated earnings of $50.6 million, up 5 per cent, providing the cash generation needed to support investment in CORIS.
CORIS has progressed through controlled market releases in Australia, the UK, Ireland and the US. The system has secured approvals in Australia, Europe and the UK, as well as its first FDA 510(k) clearance in the US.
Nanosonics plans to launch CORIS commercially in Australia, the UK and Ireland in the first half of 2027, with the US to follow. Initial revenue is expected to be in the low single-digit millions as the company increases spending on market development, customer acquisition and launch capability.
The company said the investment will lift 2027 operating expenses by an expected 10 per cent to 15 per cent, to between $156 million and $163 million. Revenue is forecast to rise between 8 per cent and 12 per cent at constant currency, to between $220 million and $228 million.
The company ended 2026 with $155.2 million in cash and no debt. It has also approved a further on-market share buyback of up to $40 million.
The buyback follows the $20 million program completed in 2026 and reflects management’s view that the company has sufficient financial capacity to pursue its growth agenda while returning capital to shareholders.
